Dr Morimoto has over 25 years of industry experience leading project teams in the development of innovative medicines for neurodegenerative diseases including Parkinson’s, Alzheimer’s, ALS and frontotemporal dementias. Previously, Bruce held leadership roles at Alkahest, Celerion, Cerecin and Allon Therapeutics, and works closely with the Michael J Fox Foundation, chairing one of their scientific review panels. He is an advisor to several biotech companies. Bruce started his career on the faculty in the Chemistry Department at Purdue University. Bruce earned his doctorate in biochemistry from UCLA and completed a postdoctoral fellowship at the University of California Berkeley.